Back to results

CompletedPhase 3

Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 Diabetes

NCT01497522

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Novartis Investigative Site

Fukuoka, Fukuoka, Japan

+19 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2011-12
Enrollment: 183 participants
Sponsor: Novartis Pharmaceuticals
Purpose: treatment

Locations (20)

Novartis Investigative SiteFukuoka, Fukuoka, Japan
Novartis Investigative SiteFukuoka, Fukuoka, Japan
Novartis Investigative SiteKitakyushu, Fukuoka, Japan
Novartis Investigative SiteKurume, Fukuoka, Japan
Novartis Investigative SiteOhkawa-city, Fukuoka, Japan
Novartis Investigative SiteKawasaki, Kanagawa, Japan
Novartis Investigative SiteYokohama, Kanagawa, Japan
Novartis Investigative SiteKyoto, Kyoto, Japan
Novartis Investigative SiteKyoto, Kyoto, Japan
Novartis Investigative SiteTakatsuki, Osaka, Japan
Novartis Investigative SiteAgeo, Saitama, Japan
Novartis Investigative SiteBunkyo-ku, Tokyo, Japan
Novartis Investigative SiteEdogawa-ku, Tokyo, Japan
Novartis Investigative SiteHachiōji, Tokyo, Japan
Novartis Investigative SiteKiyose, Tokyo, Japan
Novartis Investigative SiteMinato-ku, Tokyo, Japan
Novartis Investigative SiteMinato-ku, Tokyo, Japan
Novartis Investigative SiteNerima-ku, Tokyo, Japan
Novartis Investigative SiteShinagawa-ku, Tokyo, Japan
Novartis Investigative SiteToshima-ku, Tokyo, Japan

Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 Diabetes — TrialFind